Please find below the current areas of interest for Vaccines Human Subject Research - 2024 Cycle 1.

[RSV]
• Studies on risk factors of RSV disease, burden of disease and downstream impact/sequela in adults at increased risk of RSV diseases.
• Studies to assess GSK's RSV vaccine's immunogenicity and/or real-world effectiveness/impact in adult population at increased risk of RSV disease.
• Studies to assess vaccine-induced immunity mechanisms against RSV in adults.

[Neisseria]
• Effectiveness, impact, and duration of protection of 4CMenB/MenACWY-CRM vaccination programs in specific ages and settings, including IMD and carriage.
• Short- and long-term impact of IMD on quality of life of patients, caregivers and healthcare systems.

[Pertussis]
• Pertussis burden of diseases in adults and patients with chronic diseases.

[Rotavirus]
• Impact of Rotavirus vaccination on strain epidemiology.

[Streptococcus Pneumoniae]
• Studies to investigate the evolving serotype-specific pneumococcal disease burden (incl. epidemiological and/or economic endpoints) in adult and pediatric populations.

[Hepatitis]
• Long-term protection with hepatitis vaccines in infant and adult populations.

[Herpes Zoster]
• Studies to further understand the burden and impact of HZ and its complications, including impact on underlying conditions.
• Studies to further understand the benefits of HZ prevention in indicated populations, including but not limited to cardiovascular risks and impact on concurrent underlying chronic diseases.
• Studies to assess GSK's recombinant zoster vaccine immunogenicity and/or real-world effectiveness/impact in adult populations at risk of Zoster disease, including those with chronic medical conditions

[Varicella]
• Severity and incidence of complication / hospitalisation for Varicella disease.